CHAIN Biotech

Executive Summary

CHAIN Biotech is a UK-based immuno-therapeutics company founded in 2018, headquartered in Cambridge. The company specializes in developing oral vaccines and immuno-therapies for the lower gastrointestinal tract using a proprietary live biotherapeutic delivery platform. This platform leverages engineered bacteria to deliver therapeutic payloads directly to the gut, aiming to modulate immune responses and treat a range of gastrointestinal and systemic diseases. Currently, all therapeutic candidates are in pre-clinical development, indicating an early stage of clinical readiness. The company's approach is differentiated by its focus on oral administration, which could improve patient compliance and enable targeted delivery to the gut microbiome.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 1 Clinical Trial for Lead Candidate30% success
• 2026Pre-Clinical Data Publication in Peer-Reviewed Journal70% success
• Q4 2026Licensing or Partnership Deal for Platform Technology25% success